One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Sotera Health Company logo
Sotera Health Company SHC
$ 17.89 0.03%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Sotera Health Company Financial Statements 2025-2011 | SHC

Annual Financial Statements Sotera Health Company

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.75 B 3.48 B 4.87 B 4.69 B 6.01 B 7.42 B - - - - - - - - -

Shares

284 M 283 M 281 M 280 M 279 M 284 M - - - - - - - - -

Historical Prices

16.7 12.3 17.3 16.7 21.5 26.1 - - - - - - - - -

Net Income

77.9 M 44.4 M 51.4 M -408 M 117 M -38.6 M -20.8 M -5.87 M - - - - - - -

Revenue

1.16 B 1.1 B 1.05 B 1 B 931 M 818 M 778 M 746 M - - - - - - -

Cost of Revenue

518 M 498 M 472 M 447 M 413 M 375 M 383 M - - - - - - - -

Gross Profit

646 M 602 M 577 M 557 M 519 M 444 M 395 M 357 M - - - - - - -

Operating Income

- 298 M 277 M 248 M 257 M - 184 M - - - - - - - -

Interest Expense

8.55 M 5.31 M 7.37 M 6.44 M 15.2 M 9.41 M 7.25 M - - - - - - - -

EBITDA

94.9 M 382 M 353 M 313 M 321 M 63.3 M 248 M 224 M - - - - - - -

Operating Expenses

- 305 M 300 M 309 M 262 M - 206 M 191 M - - - - - - -

General and Administrative Expenses

253 M 243 M 237 M 246 M 198 M 179 M 147 M 133 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Sotera Health Company

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

286 M 285 M 284 M 284 M 284 M 283 M 283 M 282 M 281 M 281 M 281 M - 280 M 280 M 280 M - 279 M 279 M 279 M 284 M 232 M 232 M 232 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

53.6 M 26.6 M 48.4 M 7.96 M -13.3 M 17 M 8.75 M 6.32 M -13.7 M 23.5 M 2.84 M - 25.1 M 30.4 M 30.6 M - 27.4 M 42.6 M 10.8 M - 10 K 7.02 M -1.96 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

321 M 280 M 311 M 294 M 255 M 285 M 277 M 248 M 263 M 255 M 221 M - 249 M 267 M 237 M - 226 M 252 M 212 M - 200 M 213 M 188 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

143 M 133 M 134 M 128 M 119 M 127 M 124 M 121 M 117 M 116 M 109 M - 113 M 116 M 108 M - 101 M 108 M 96.8 M - 92.5 M 94.1 M 91.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

178 M 147 M 178 M 167 M 135 M 158 M 153 M 127 M 146 M 140 M 112 M - 136 M 150 M 129 M - 126 M 144 M 115 M - 108 M 119 M 96.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - 80.5 M 76.8 M 53.2 M 76.1 M 63.2 M 33.4 M - 63.2 M 71.5 M 53.5 M - 65.7 M 78.3 M 46.4 M - 47 M 61.7 M 44.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

2.85 M 960 K 464 K 5.82 M 241 K 2.84 M 1.52 M -961 K -427 K 2.47 M 1.25 M - 1.71 M -485 K 2.97 M - 693 K 2.76 M 3.89 M - 3.14 M 4.36 M -3.15 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

53 M - - - - - - 73.5 M - - 52.3 M - 111 M 71.5 M 69.4 M - 113 M 78.3 M 61.7 M - 94.4 M 93.2 M 61 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - 77.5 M 76 M 73.9 M 69.9 M 76.4 M 78.1 M - 72.8 M 78.9 M 75.4 M - 59.9 M 65.5 M 69 M - 60.5 M 57.2 M 51.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

68.2 M 68.2 M 63.3 M 68.9 M 63.1 M 62 M 60.6 M 58.2 M 54.1 M 60.3 M 61.9 M - 57.1 M 63.1 M 59.5 M - 44 M 49.8 M 52.5 M - 45.6 M 42.7 M 37.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Sotera Health Company SHC
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Sotera Health Company plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Natera Natera
NTRA
$ 393.44 2.54 % $ 53.8 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
$ 46.13 0.15 % $ 10 B niderlandNiderland
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 8.03 1.26 % $ 2.88 B irlandaIrlanda
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.0 0.36 % $ 26.1 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 560.36 2.41 % $ 45.1 B usaUSA
Personalis Personalis
PSNL
$ 15.65 0.19 % $ 1.4 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 12.91 0.29 % $ 544 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 6.47 2.11 % $ 28.6 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
$ 1.85 3.0 % $ 5.39 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 3.98 4.82 % $ 369 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.73 0.73 % $ 519 M usaUSA
Neuronetics Neuronetics
STIM
$ 1.89 3.45 % $ 125 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 172.97 0.07 % $ 49.1 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 300.15 0.79 % $ 14.9 B usaUSA
Biodesix Biodesix
BDSX
$ 23.66 3.0 % $ 179 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 12.9 6.78 % $ 136 M chinaChina
Bioventus Bioventus
BVS
$ 13.3 0.94 % $ 886 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 0.65 11.61 % $ 865 K usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 19.81 1.57 % $ 610 M usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA
Illumina Illumina
ILMN
$ 262.54 0.3 % $ 40.7 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 317.95 0.09 % $ 26.5 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 99.7 0.03 % $ 6.73 B usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA